1 Hiltrud Brauch, PhD, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, University of Tübingen, Tübingen, Germany, and German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Werner Schroth, PhD and Thomas Mürdter, PhD, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tübingen, Tübingen, Germany; and Matthias Schwab, MD, Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, University of Tübingen, Tübingen, Germany, and German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.